Haleon (LON:HLN) Posts Earnings Results

Haleon (LON:HLN) posted its earnings results on Thursday. The company reported GBX 8.60 earnings per share for the quarter, Digital Look Earnings reports. Haleon had a net margin of 15.11% and a return on equity of 10.30%.

Haleon Stock Performance

Haleon stock opened at GBX 366.50 on Friday. The company has a debt-to-equity ratio of 52.26, a current ratio of 0.92 and a quick ratio of 0.93. Haleon has a 12 month low of GBX 317.80 and a 12 month high of GBX 416.10. The company has a fifty day moving average price of GBX 349.45 and a two-hundred day moving average price of GBX 363.11. The company has a market cap of £32.28 billion, a PE ratio of 19.81, a P/E/G ratio of 1.49 and a beta of 0.24.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 370 price target on shares of Haleon in a report on Thursday, April 30th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 400 target price on shares of Haleon in a research note on Friday. JPMorgan Chase & Co. reduced their price target on Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a research report on Thursday, June 25th. Berenberg Bank restated a “buy” rating and issued a GBX 512 price target on shares of Haleon in a report on Thursday, April 30th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Haleon from GBX 325 to GBX 335 and gave the company a “sell” rating in a research report on Friday. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of GBX 395.33.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.